iBio (NYSE:IBIO) Now Covered by Oppenheimer

Oppenheimer assumed coverage on shares of iBio (NYSE:IBIO) in a report released on Tuesday, MarketBeat.com reports. The firm issued an outperform rating and a $5.00 price target on the stock.

Several other equities research analysts have also commented on IBIO. Chardan Capital reiterated a “buy” rating and set a $5.00 price objective on shares of iBio in a research note on Wednesday, June 25th. Leerink Partners began coverage on iBio in a research note on Friday. They set an “outperform” rating and a $2.00 price objective for the company. Three analysts have rated the stock with a Buy rating, According to MarketBeat.com, iBio presently has a consensus rating of “Buy” and a consensus target price of $4.00.

iBio Price Performance

NYSE:IBIO opened at $1.11 on Tuesday. iBio has a 12 month low of $0.56 and a 12 month high of $6.89. The stock has a 50 day moving average of $0.83 and a two-hundred day moving average of $0.84. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.05. The firm has a market cap of $22.48 million, a P/E ratio of -0.64 and a beta of 0.89.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in iBio stock. Iridian Asset Management LLC CT acquired a new position in iBio, Inc. (NYSE:IBIO) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 58,205 shares of the company’s stock, valued at approximately $234,000. Iridian Asset Management LLC CT owned 0.59% of iBio as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 7.90% of the company’s stock.

iBio Company Profile

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.